Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction
Authors' conclusion
In older patients with MI and multivessel disease, physiology-guided complete revascularization reduces ischemic events irrespective of diabetes status
Study context
- Population
- Patients aged ≥75 years with myocardial infarction (MI) and multivessel disease; 463 (32%) had diabetes463 with DM
- Participants
- 1,445 patients
- Comparison
- Physiology-guided complete revascularization vs culprit-only revascularization, by diabetes status
- Primary endpoint
- Composite of:
- Death
- MI
- Stroke
- Revascularization
- Follow-up
- 3 years
Primary result
As reported in the abstract
Composite of:
- Death
- MI
- Stroke
- Revascularization
Physiology-guided complete vs Culprit-onlyHazard ratio (95% CI)P value
Patients with diabetes
0.70(0.50–0.97)
Patients without diabetes; no effect modification by diabetes status
0.75(0.58–0.97)
P = 0.712for interactionSecondary outcomes
Diabetes vs no diabetes (adjusted), primary endpoint · 3 years
- HR (95% CI) for diabetes
- 1.26 (1.02-1.56)
- Adjusted for baseline characteristics
Diabetes vs no diabetes (adjusted), heart failure · 3 years
- HR (95% CI) for diabetes
- 1.35 (1.01-1.83)
- Adjusted for baseline characteristics
Key secondary endpoint: CV death or MI
- Similar consistency across diabetes status
Safety
Safety endpoint: contrast-associated acute kidney injury, stroke, or BARC type 3-5 bleeding
- Similar consistency across diabetes status
Original publication
Diabetes does not attenuate the benefit of physiology-guided complete revascularization in older patients with myocardial infarction. Cardiovasc Diabetol. Published 14 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →